14.00 - 16.00
CLINICAL RESEARCH
ASSOCIATES/ TRIAL
NURSES
The Mission
The mission of the clinical research team is to contribute to the advancement of treatment for childhood cancer as well as the integrity of the research itself.
The CRC/TN play an essential role in the conduct of clinical research and are crucial in assuring that the scientific accuracy of data is of highest quality.
Conference Room 1
Agenda of this meeting:
• Personal presentation of each attending CRA/TN
• Presentation of the study center structure, organization in each country and open studies (HR-NBL, Lines, Beacon, Veritas, OMS-DES 2011, NB-SCI, RIST, MIITOP, TOTEM) (Please prepare a quick and short presentation, two slides)
• Comparison and discussion on differences between countries
• Discussion about the creation of a SIOPEN network group of CRC/TN
• Presentation of the HR2 NBL database
• Open questions
• Organization of future educational sessions and training: subjects of needs and interest.
17.00 - 19.00
LINES
Specialty Committee meeting
• Presentation of current status on LINES trial
- Database Accrual
• Road map for Database cleaning
- Missing clinical data
- Next wave of queries
- Current needs
Open questions and discussion
• Intermediate risk Study
• Low risk study
- Update on G1 survey: why Randomization did not work?
- What is going to happen with “LR patient” that required further investigation
Open questions and discussion
• Surgery substudy
Open questions and discussion
• What´s next?
Open questions and discussion
Conference Room 1
09.30 - 10.30
NUCLEAR MEDICINE
Physics Joint Session
Seminar and Discussion
Theranostic and Dosimetry : VERITAS
Collecting multi tracers radio metabolic therapies casistic
Organs toxicity by Chemo, Radio and Radiometabolic Therapies: a future challenge in “chronic” disease
Conference Room 2
11.00 - 13.00
11.00 - 11.15
11.20 - 11.40
11.40 - 12.00
12.00 - 12.20
12.20 - 12.40
12.40 - 13.00
TRANSLATIONAL
RESEARCH
Introduction: Structure and functional updates about the TSC
SILK - SIOPEN International Liquid Biopsy Network
Liquid biopsy-based monitoring of TERT breakpoints in patients with neuroblastoma
Presentation of the collaborative grant application “Horizon Europe 2020”
European risk stratification for children
with neuroblastoma (EURIS)
BEACON-Neuroblastoma biomarker studies; circulating adrenergic Neuroblastoma mRNAs predict outcomes in children with relapsed and refractory Neuroblastoma
Conference Room 2
14.00 - 15.00
14:00 – 14:10
14:10 – 14:20
14:20 – 14:30
14:30 – 14:40
14:40 – 14:50
14:50 – 15:00
QOL- LTO COMMITTEE
Introduction Committee Activities
Ototoxicity in Neuroblastoma
Outline of the Ototoxicity Study &
Spanish Pilot
Audiometry and QoL issues
Genetic Testing
Discussion, Prospective
Conference Room 2
15.00 - 16.00
15:00-15:05
15:05-15:20
15:20-15:35
15:35-15:50
15:50-16:00
JOINT QOL- LTO – PALLIATIVE CARE
Introduction
SIOPE Palliative Care Working Group
Speaking about the unspeakable: Support through breaking down taboos
How can SIOPEN include Palliative Care on its activities?
Discussion
Conference Room 2
16.30 – 17.00
16.30 – 16.45
16.45 – 17.00
JOINT QOL- LTO – NUCLEAR MEDICINE
Single center study of thyroid protection
Discussion
Conference Room 2
17.00 – 18.00
17:00 -17:20
17:20 -18:00
Radiology - Nuclear Medicine
Committee, joint Session
Hybrid imaging in HR-NB.
Discussion about:
- Local control: Definition of MRI/MIBG/F-DOPA value in the HR NBL
- Additional value of MIBG/F-DOPA and PET-MRI in metastatic disease
Conference Room 2
08.30 - 10.30
08.30 - 08.45
08.45 - 09.25
09.25 - 10.00
10.00 - 10.15
10.15 - 10.30
IMMUNOTHERAPY
Welcome and news from trials with dinutuximab beta
Current status and perspectives of CAR-T cell therapy in neuroblastoma
Update of the haplo-immunotherapy concept
Models to test immunotherapy in neuroblastoma
Discussion, Summary
LARGE ROOM
11.00 - 13.00
SPINAL CANAL
INVASION
1. Study update and discussion:
o Clinics
o Statistics
2. Publication report
3. Future perspective and conclusions
4. Case presentation discussions
LARGE ROOM
14.00 - 16.00
14.00 - 14.15
14.15 - 14.25
14.25 - 14.45
14.45 - 14.55
14.55 - 15.05
15.05 - 15.15
15.15 - 15.30
15.30 - 16.00
NEW DRUG
DEVELOPMENT AND
RELAPSE
> High risk
> Relapse
> Early phase
- INTRODUCTION
- Managing relapsed/refractory disease
lessons learnt
BEACON
Trials library
Discussion (practical approach in absence of trial)
Ongoing work on trial development
- BEACON 2
- Relapse consolidation trial
- DFMO + AMXT1501 with cyclo topo
- Other trial opportunities and discussion
Molecular testing lessons
MAPPYACTS/iTHER/SM PAEDS NB data
LARGE ROOM
16.30 – 18.00
16.30 - 16.40
16.40 - 16.45
16.45 - 17.00
17.00 - 17.15
17.15 - 17.30
17.30 - 17.45
17.45 - 18.00
NEW DRUG
DEVELOPMENT AND
RELAPSE
> High risk
> Relapse
> Early phase
Telomere lengthening
Discussion
Building the future, including incorporating immunotherapy
Biomarkers
Combinations with ALK inhibitors
IT and other combinations
Anti-CD47 combination with chemo
Discussion
Next Steps Discussion
LARGE ROOM